We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Sex Hormone–Binding Globulin Is a Biomarker for Cardiovascular Disease Risk Independent of Total Testosterone Concentration

By LabMedica International staff writers
Posted on 03 Jan 2022
The blood protein sex hormone–binding globulin (SHBG) has been shown to be a biomarker that predicts greater risk of myocardial infarction and lower risk of ischemic stroke and heart failure in men between the ages of 40 and 69.

Investigators at University of Western Australia (Perth) conducted a study to analyze associations of serum total testosterone and SHBG with incident cardiovascular events in men. More...
Testosterone circulates in the bloodstream, with about 54% loosely bound to serum albumin and about 44% bound tightly to SHBG. Only a very small fraction (1 to 2%) is unbound, or "free," and thus biologically active and able to enter a cell and activate its receptor. Thus, bioavailability of sex hormones is influenced by the level of SHBG.

For this study, the investigators analyzed serum samples obtained from 210,700 men aged 40 to 69 for a period of nine years. During this time, outcomes of incident myocardial infarction (MI), hemorrhagic stroke (HS), ischemic stroke (IS), heart failure (HF), and major adverse cardiovascular events (MACE) were observed and associated with measured levels of testosterone and SHBG and calculated levels of free testosterone.

Results revealed that 4.2% (8790) of the men had an incident cardiovascular event during the nine year course of the study. Lower testosterone concentrations were not associated with incident MI, HS, IS, HF, or MACE after adjustment for key variables. The incidence of MACE was significantly lower for men with lower calculated free testosterone values. Lower SHBG concentrations were associated with higher incidence of MI and lower incidence of IS and HF, but not with HS or MACE.

These results allowed the investigators to conclude, "Men with lower SHBG concentrations have higher risk for MI but lower risk for HF, indicating a role for SHBG as a biomarker for various cardiovascular risks, independently of total testosterone concentrations."

The study was published in the December 28, 2021, online edition of the journal Annals of Internal Medicine.

Related Links:
University of Western Australia


New
Gold Member
Latex Test
SLE-Latex Test
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Host Response Immunoassay Test
MeMed BV
New
Pan-Cancer Panel
TruSight Oncology 500
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.